Nuvation Bio, Eisai enter exclusive taletrectinib license agreement

Nuvation Bio (NUVB) and Eisai (ESAIY) announced an exclusive license and collaboration agreement that significantly expands the long-term global footprint of taletrectinib. Taletrectinib is a highly selective, next-generation oral treatment currently approved for patients living with advanced ROS1-positive non-small cell lung cancer in the U.S., China and Japan. Eisai will now have exclusive development, registration and commercialization rights for taletrectinib for the treatment of ROS1+ NSCLC in Europe, the Middle East, North Africa, Russia, Turkey, Canada, Australia, New Zealand, Singapore, the Philippines, Indonesia, Thailand, Malaysia, Vietnam and India. Nuvation Bio will continue to lead global development and retain full U.S. commercial rights, maintaining its strong focus on U.S. launch activities and ongoing pivotal studies of taletrectinib across early- and late-stage ROS1+ NSCLC. Under the terms of the exclusive license and collaboration agreement, Nuvation Bio will receive EUR 50M upfront and up to EUR 145M in regulatory and commercial milestone payments, as well as double-digit tiered royalties up to the high-teens as a percentage of future net sales in the licensed territories. Following the upfront payment, Nuvation Bio will receive the first milestone payment of EUR 25M from this transaction upon achievement of EU regulatory approval of taletrectinib.